RecruitingNot ApplicableNCT06512441

Vitamin B6 Aids in Treating Inflammatory Bowel Disease

Vitamin B6 Assists in the Treatment of Inflammatory Bowel Disease

Sponsor

Changhai Hospital

Enrollment

220 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Inflammatory Bowel Diseases

Summary

Patients with IBD are randomized to oral administration of VitaminB6 and placebo based on the standard treatment, exploring whether VitaminB6 can increasee the clinical remission rateand improve the treatment effect of IBD patients.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Vitamin B6 Tablets for people with inflammatory bowel diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVitamin B6 Tablets

The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.

DRUGPlacebo

The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.

Locations(1)

Changhai Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06512441

Related Trials

BOOM-IBD2 Pivotal Clinical Trial

NCT0657166919 locations

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395223 locations

A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea

NCT075207471 location

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883226 locations

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT0484460667 locations